Hepatocellular carcinoma (HCC) is the fourth leading. Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men

Size: px
Start display at page:

Download "Hepatocellular carcinoma (HCC) is the fourth leading. Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men"

Transcription

1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8: Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men ROHIT LOOMBA,*, HWAI-I YANG, JUN SU, DAVID BRENNER,* UCHENNA ILOEJE, and CHIEN-JEN CHEN, *Division of Gastroenterology and Division of Epidemiology, University of California at San Diego, La Jolla, California; Genomics Research Center, Academia Sinica, Taipei, Taiwan; Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut; and Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan BACKGROUND & AIMS: Body mass index (BMI) and alcohol use are risk factors for hepatocellular carcinoma (HCC). We performed a prospective study to determine if these factors have synergistic effects on HCC risk. METHODS: Over 14 years, we followed up 2260 Taiwanese men from the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer Hepatitis B Virus (REVEAL HBV) Study Cohort who tested positive for the hepatitis B surface antigen (mean age, y; mean BMI, 24 3 kg/m 2 ); 20% reported alcohol use. Incident HCC cases were identified via linkage to the national cancer registry. Multivariate-adjusted hazard ratio (HR) and 95% confidence interval (CI) were estimated using Cox-proportional hazards models. RESULTS: In univariate analysis, the interaction between BMI and alcohol predicted incident HCC (P.029). Alcohol use and extreme obesity (BMI 30 kg/m 2 ) had synergistic effects on the risk of incident HCC in analyses adjusted for age (HR, 3.41; 95% CI, ; P.025) and multivariables (HR, 3.40; 95% CI, ; P.025). The relative risk estimate for the interaction and the attributable proportion from the interaction and synergy index were 1.59, 0.52, and 4.40, respectively; these indicate a multiplicative interaction between alcohol use and extreme obesity. In an analysis stratified into 4 World Health Organization categories of BMI and alcohol use, the risk of incident HCC increased in overweight (HR, 2.4; 95% CI, ), obese (HR, 2.0; 95% CI, ), and extremely obese (HR, 2.9; 95% CI, ) users of alcohol (P for trend.046). CONCLUSIONS: Obesity and alcohol have synergistic effects to increase the risk of incident HCC in hepatitis B surface antigen positive men. Lifestyle interventions might reduce the incidence of HCC. Keywords: Hepatocellular Carcinoma; Epidemiology; Cirrhosis; Nutrition. Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide. 1 The World Health Organization (WHO) estimates that HCC leads to 610,000 deaths each year globally. 1 Based on the WHO database, the burden of HCC is increasing and by the year 2030 it will become the third leading cause of cancer mortality, replacing colon cancer. 1 The Surveillance, Epidemiology, and End Results database of the National Cancer Institute also suggests that both incidence and mortality related to HCC is increasing 2,3 and will continue to increase until 2030 in the United States. 4 Despite improvement in treatment modalities, from 2000 to 2005, HCC incidence and mortality rates continue to increase. 5 Preventive measures in addition to treatment advances are needed to effectively control this global epidemic of HCC. Viral hepatitis B is the leading cause of HCC worldwide. Body mass index (BMI) and alcohol use are modifiable and independent risk factors for HCC and further modify the risk of individuals with chronic hepatitis B and C. 6 Studies suggest that obesity increases the risk of HCC by approximately 2-fold. 7,8 There is conflicting evidence whether alcohol use modifies the risk of HCC independent of or via interaction with smoking. 6,9 12 Here, we examine the joint effect of alcohol and obesity on incident HCC risk in a prospective cohort study. Obesity and alcohol both lead to fatty liver disease. Nonalcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease in the United States and may lead to cirrhosis and HCC in a subset of individuals. 13 Several groups have reported that fatty liver and/or nonalcoholic steatohepatitis (NASH) increase the risk of HCC. 14 Up to 50% of HCC cases in the United States are not related to hepatitis B or C. 14 Bugianesi et al 15 showed that metabolic syndrome traits are seen more commonly in cryptogenic cirrhosis patients with HCC versus matched controls. Marrero et al 13 conducted a large, single-center study of 135 HCC cases and reported that NAFLD accounted for 47% of the HCC cases in patients with cryptogenic cirrhosis and 11% of all cases of HCC. Hashimoto et al reported a prospective study including 137 NASH patients, and showed that the 5-year cumulative incidence of HCC in NASH was 7.6%. 16 Therefore, NAFLD and NASH are emerging as major risk factors for HCC. Previous studies have shown that alcohol and obesity synergistically increase the risk of subclinical and clinical liver injury. 17 However, limited data exist on whether alcohol and obesity are additive or multiplicative in increasing the risk of HCC in patients with hepatitis B virus (HBV) infection. We hypothesize that obesity and alcohol are synergistic (multiplicative, not just additive) in increasing the risk of future Abbreviations used in this paper: ALT, alanine aminotransferase; AP, attributable risk proportion due to interaction; BMI, body mass index; CI, confidence interval; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazards ratio; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; RERI, relative excess risk due to interaction; REVEAL HBV, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer Hepatitis B Virus; SI, synergy index; WHO, World Health Organization by the AGA Institute /$36.00 doi: /j.cgh

2 892 LOOMBA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 10 development of HCC. To test this hypothesis, we conducted a prospective study in a well-characterized (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer Hepatitis B Virus [REVEAL HBV]) cohort to examine the joint effect of obesity and alcohol on the future risk of HCC in men with chronic HBV infection over a 14-year follow-up period after adjusting for confounding variables using Cox-proportional hazards analysis. Methods Study Population A detailed description of the recruitment and blood sample collection and assay procedures has been reported previously and well characterized 6,18,19 : 2260 hepatitis B positive men who were part of the REVEAL HBV cohort 6,18,19 were included in this analysis. Information on demographic and lifestyle factors was collected via a structured personal interview by well-trained public health nurses. Overnight fasting blood samples were collected at baseline, and tests on serum hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV-DNA levels were performed using commercial kits and detailed laboratory procedures as described previously. 19 None of them had co-infection with hepatitis C. Because more than 99% of women in this cohort do not drink, they were not included in the analysis because of a lack of power to test our hypothesis. This was decided before conducting data analyses. All participants gave informed consent to participate in the REVEAL HBV study, and the data collection procedures were reviewed and approved by the Institutional Review Board of the College of Public Health, National Taiwan University. Duration of Follow-Up Evaluation Participants were followed up until June 30, 2004, with more than 14 years of follow-up evaluation. Assessment of Exposure BMI was defined as weight (kg) divided by the square of height (in meters). Weight and height were measured by a nurse at the baseline visit and was categorized into normal ( 23 kg/m 2 ), overweight (23 to 25 kg/m 2 ), obese (25 to 30 kg/ m 2 ), and extremely obese ( 30 kg/m 2 ) based on the guidelines for the adult Asian population published by the WHO. 20 Alcohol Alcohol use was ascertained at the baseline visit with a questionnaire as previously described. 21 Individuals were asked about habit of alcohol consumption (yes/no), starting age, and present alcohol use (yes/no). Duration of alcohol use (in years) was also documented. Alcohol drinkers were defined as having alcohol consumption at least 4 days per week for at least 1 year. Identification of Incident Hepatocellular Carcinoma Baseline screening for HCC was performed with an abdominal ultrasonographic examination in all participants. Cirrhosis was diagnosed using abdominal ultrasonography with a systematic and quantitative scoring algorithm, which was determined by the appearance of the liver surface and the liver parenchyma as well as by the size of the hepatic vessel and the spleen. 22,23 Unique national identification numbers were used to link with the computerized national cancer registry profiles in Taiwan to identify newly diagnosed HCC cases between January 1, 1991, and June 30, Subjects who had HCC identified through ultrasound screening at the baseline visit, through linkage to the national cancer registry, or from personal interview before or at enrollment were excluded from the analysis. The Taiwan nationwide cancer registry system was started in 1978, which has updated, accurate, and complete information on HCC. Because not all cases of HCC reported to the national cancer registry had histologic confirmation, chart reviews were performed on 164 HCC cases in HBsAg-positive carriers to further validate the primary HCC diagnosis. Therefore, all HCC cases included in this study met at least one of the following criteria: histopathologic confirmation, detection by at least 2 imaging tools (ultrasonography, angiography, or computed tomography), or 1 imaging diagnosis with a serum- fetoprotein level of 400 ng/ml or greater. Statistical Analysis Baseline characteristics of the population were described as mean (standard deviation) for continuous variables and proportions for categoric variables. Cox-proportional hazards analysis was conducted to determine the hazards of incident HCC over 14 years of follow-up evaluation and reported as a relative risk estimate. Univariate, followed by multivariable models (adjusted for age, BMI, alcohol use, serum HBV-DNA level when applicable, smoking, serum alanine aminotransferase [ALT] level, HBeAg status [yes/no], and cirrhosis at baseline visit) were examined. Joint effects of extreme obesity (yes/no) and alcohol use (yes/no) (and duration and dose of alcohol use) were examined using Cox-proportional hazards models. Hazard ratios (HRs) and their respective 95% confidence intervals (CIs) were reported. Incidence curves across 4 BMI-alcohol categories also were examined. Estimate of interaction on a multiplicative scale. Joint effects of alcohol and obesity were estimated using relative excess risk resulting from interaction (RERI), attributable risk proportion resulting from interaction (AP), and synergy index (SI), and their respective 95% CIs as previously described. 24,25 RERI is an estimate of excess risk that is directly attributable to the interaction between 2 exposures. AP is defined as the proportion of risk that is attributable to the interaction between the 2 exposure variables. SI is a ratio that estimates whether a synergistic (SI, 1) or antagonistic (SI, 1) interaction exists between 2 exposures. A multiplicative interaction is suggested by the following scores: an RERI greater than 1.5, an AP greater than 0.25, and an SI greater than Joint effects of body mass index and alcohol. Joint effects between WHO BMI categories and alcohol use (yes/no) were performed on hazards of HCC. Furthermore, joint effects of BMI WHO categories and duration of alcohol use ( 10, 10 19, and 20 y) were examined. Sensitivity analysis. Joint effects between BMI quartiles (1, lowest; through 4, highest), and alcohol use (yes/no) were analyzed using proportional hazards models with incident HCC as the outcome. In addition, joint effects of BMI quartiles and duration of alcohol use (no alcohol, 1 19 y, 20 y) was examined. A 2-tailed P value of.05 or less was considered statistically significant. All analyses were conducted using SAS statistical software (version 8.01; SAS Institute Inc, Cary, NC).

3 October 2010 OBESITY, ALCOHOL, AND HCC RISK 893 Results Baseline Characteristics A total of 2260 Taiwanese men who were HBsAg-positive were included in this analysis. The mean ( standard deviation) age and BMI were 45.8 ( 10) years and 23.9 ( 3) kg/m 2, respectively. A fifth of participants reported alcohol use and 53.8% of the population were classified as smokers. A majority (83.9%) of individuals were HBeAg-negative, the prevalence of increased ALT levels ( 45 U/L) was 7.6%, and only 2.7% of all participants had cirrhosis at baseline. Prevalence of cirrhosis was similar in normal weight, overweight, obese, and extremely obese participants. Table 1 shows the baseline characteristics of the patients included in the study. Risk Factors for Future Development of Hepatocellular Carcinoma There were a total of 135 cases of HCC over 41,778 person-years of follow-up evaluation. Median age (range) at Table 1. Baseline Characteristics of the Participants Included in the Study Characteristic 2260 men Age, y Mean standard deviation Median (25th percentile 75th percentile) 45 (37 54) (33.5) (27.4) (28.5) (10.6) BMI, kg/m 2 Mean standard deviation Median (25th percentile 75th percentile) 23.6 ( ) 23 (normal weight) 931 (41.3) 23 to 25 (overweight) 554 (24.6) 25 to 30 (obese) 684 (30.3) 30 (extremely obese) 88 (3.9) (96.1) (3.9) Cigarette smoking No 1044 (46.2) Yes 1214 (53.8) Alcohol consumption No 1808 (80.2) Yes 447 (19.8) HBeAg status Positive 363 (16.1) Negative 1897 (83.9) ALT level, U/L (55.7) (36.7) (7.6) HBV DNA, copies/ml Median (25th percentile 75th percentile) 10 3 ( ) 10, (69.9) 10, (30.1) Diabetes No 2200 (97.4) Yes 58 (2.6) Cirrhosis No 2198 (97.3) Yes 62 (2.7) diagnosis of HCC was 59 (36 76) years. We then conducted Cox-proportional hazards analysis to identify predictors of incident HCC in this cohort. The univariate analysis (Table 2) showed that age, alcohol use, HBeAg status, HBV-DNA levels, increased ALT levels, cirrhosis at baseline, and interaction between alcohol and BMI (P.029) were statistically significant predictors of incident HCC over 14 years of follow-up evaluation. Multivariate-adjusted analysis showed that age, alcohol use, HBeAg status, HBV-DNA levels, and cirrhosis at baseline were statistically significant independent predictors of incident HCC over 14 years of follow-up evaluation. Although the hazards of incident HCC were increased with BMI, smoking, increased ALT level, and interaction between BMI and alcohol, the results were not significant. The risk of incident HCC was highest in alcohol users with a BMI of 30 kg/m 2 or greater as shown in Figure 1. A total of 19.8% of the participants reported alcohol use. The incidence rate of HCC among alcohol users versus nonusers was 852 cases of HCC versus 253 cases of HCC per 100,000 personyears of follow-up evaluation, respectively (Table 2). Alcohol use was associated with increased risk of incident HCC both in unadjusted and multivariate adjusted models with an HR of 1.91 (95% CI, ; P.001) and an HR of 1.54 (95% CI, ; P.031), respectively (Table 2). Joint Effects of Obesity and Alcohol on Incident Hepatocellular Carcinoma Joint effects of alcohol use and extreme obesity (BMI, 30) showed that the risk of HCC was increased synergistically in alcohol users who had extreme obesity compared with those without extreme obesity and nonusers of alcohol (HR, 3.1; 95% CI, ; P.028) as shown in Figure 2. Results remained consistent in both age-adjusted (HR, 3.41; 95% CI, ; P.025) and multivariable-adjusted (HR, 3.40; 95% CI, ; P.025) analyses as shown in Table 3. The Wald test of interaction between BMI and alcohol use was statistically significant (P.029). RERI, AP, and SI were 1.59 (95% CI, 1.6 to 4.79), 0.52 (95% CI, 0.09 to 1.13), and 4.40 (95% CI, ), respectively, indicating the presence of a multiplicative interaction between obesity and alcohol use. A multiplicative interaction is suggested by the following scores: an RERI greater than 1.5, an AP greater than 0.25, and an SI greater than ,26 Figure 2 shows the cumulative incidence of HCC over 14 years of follow-up evaluation across the 4 BMI-alcohol categories. Incidence rates were higher in alcohol users with a BMI less than 30 kg/m 2 than nonusers of alcohol with a BMI of 30 kg/m 2 or greater. The lowest incidence was in nonusers who had a BMI of less than 30 kg/m 2. The HCC rate among nonusers of alcohol with a BMI of less than 30 kg/m 2 and a BMI of 30 kg/m 2 or greater were 5.2% and 3.1%, respectively, and the HCC rate among users of alcohol with a BMI of less than 30 kg/m 2 and a BMI of 30 kg/m 2 or greater were 9.1% and 14.9%, respectively. The incidence rate of HCC was significantly higher in alcohol users with a BMI of 30 kg/m 2 or greater as compared with the other 3 categories (P.002). Joint Effects of Body Mass Index Categories and Alcohol Use on Incident Hepatocellular Carcinoma We further explored at which level of BMI the hazards of incident HCC increase in alcohol users. Risk of HCC was

4 894 LOOMBA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 10 Table 2. Unadjusted and Multivariate-Adjusted Risk of Incident HCC in Men Over 14 Years of Follow-Up Evaluation Variable No. of participants Person-years of follow-up evaluation No. of HCC cases Incidence rate per 100,000 person-years Crude HR (95% CI) P value Multivariable-adjusted HR (CI) P value Age in 1-year increments 1.07 ( ) ( ).001 BMI in 1-kg/m 2 increments 1.02 ( ) ( ).90 Cigarette smoking No , Referent Referent Yes , ( ) ( ).81 Alcohol consumption No , Referent Referent Yes ( ) ( ).031 HBeAg status Negative , Referent Referent Positive ( ) ( ).001 ALT level, U/L , Referent Referent ( ) ( ).76 HBV DNA, copies/ml 10, , Referent Referent 10, , ( ) ( ).001 Cirrhosis No , Referent Referent Yes ( ) ( ).001 Alcohol/BMI (interaction) 1.12 ( ) ( ).29 higher in users of alcohol than nonusers across all BMI categories but was not increased significantly in the normal weight category (Figure 3). However, the risk synergistically increased in overweight (HR, 2.4; 95% CI, ), obese (HR, 2.0; 95% CI, ), and extremely obese (HR, 2.9; 95% CI, ) users of alcohol (P value for trend.046). We also analyzed the joint association between BMI categories and duration of alcohol use and found that the risk of HCC was highest in extremely obese individuals who had 20 years or more of alcohol use (HR, 8.2; 95% CI, ) as shown in Supplementary Figure 1. The risk of HCC was higher in overweight or obese individuals with a history of 20 or more years of alcohol use and synergistically increased with higher BMI (P value for trend.006). The results remained statistically significant for the joint effect of extreme obesity and alcohol use in age-adjusted (HR, 3.07; 95% CI, ; P.04) and multivariate-adjusted models (HR, 3.21; 95% CI, ; P.03) as shown in Table 3. Similarly, the joint effect of extreme obesity and 20 years or more of alcohol use in age-adjusted (HR, 5.93; 95% CI, ; P.001) and multivariate-adjusted models (HR, 5.17; 95% CI, ; P.003) remained statistically significant as shown in Table 3. Sensitivity Analyses Joint effects of body mass index (quartiles) and alcohol use on incident hepatocellular carcinoma. Risk of HCC was higher in users of alcohol than nonusers across quartiles 2 to 4 (Supplementary Figure 2). Participants in the highest BMI quartile who consumed alcohol had a statistically significantly increased risk of incident HCC (HR, 2.5; 95% CI, Figure 1. Risk of incident HCC is 3.1 (95% CI, ) times higher in alcohol users who have a BMI of 30 kg/m 2 or greater as compared with nonusers of alcohol with a BMI of less than 30 kg/m 2, which is suggestive of multiplicative effect. This figure shows that obesity significantly augments the risk of incident HCC in alcohol users but not in nonusers. Figure 2. This figure shows the incidence curves of development of HCC in the 4 BMI-alcohol categories. The y-axis depicts the proportion of individuals in each group who are developing HCC (0.1 representing 10% and 0.2 representing 20% of participants). The risk of incident HCC was highest in alcohol users with a BMI of 30 kg/m 2 or greater.

5 October 2010 OBESITY, ALCOHOL, AND HCC RISK 895 Table 3. Age-Adjusted and Multivariable-Adjusted Models Showing the Joint Association Between Alcohol Use and BMI With Incident HCC Over 14 Years of Follow-Up Evaluation Variable Age-adjusted HR (95% CI) P value Multivariate-adjusted HR (95% CI) a P value BMI/alcohol use 30 kg/m 2 /no 30 kg/m 2 /no 0.74 ( ) ( ) kg/m 2 /yes 1.80 ( ) ( ) kg/m 2 /yes 3.41 ( ) ( ).0176 WHO BMI categories/alcohol use b Normal weight/no Overweight/no 0.76 ( ) ( ).3713 Obese/no 0.89 ( ) ( ).8585 Extremely obese/no 0.67 ( ) ( ).5167 Normal weight/yes 1.05 ( ) ( ).6593 Overweight/yes 2.38 ( ) ( ).003 Obese/yes 1.75 ( ) ( ).3106 Extremely obese/yes 3.07 ( ) ( ).0275 WHO BMI categories/year of alcohol consumption Normal weight/0 y Overweight/0 y 0.76 ( ) ( ).394 Obese/0 y 0.89 ( ) ( ).8515 Extremely obese/0 y 0.67 ( ) ( ).5027 Normal weight/1 19 y 1.57 ( ) ( ).1882 Overweight/1 19 y 2.35 ( ) ( ).2899 Obese/1 19 y 1.61 ( ) ( ).3514 Extremely obese/1 19 y Normal weight/ 20 y 0.64 ( ) ( ).6143 Overweight/ 20 y 1.81 ( ) ( ).0811 Obese/ 20 y 1.88 ( ) ( ).4858 Extremely obese/ 20 y 5.93 ( ) ( ).0023 BMI categories/drinker c Quartile 1/no Quartile 2/no 0.93 ( ) ( ).4352 Quartile 3/no 1.09 ( ) ( ).5666 Quartile 4/no 0.72 ( ) ( ).5084 Quartile 1/yes 1.15 ( ) ( ).4477 Quartile 2/yes 1.81 ( ) ( ).1275 Quartile 3/yes 1.66 ( ) ( ).6981 Quartile 4/yes 2.39 ( ) ( ).0075 BMI categories/year of alcohol consumption Quartile 1/0 y Quartile 2/0 y 0.93 ( ) ( ).4319 Quartile 3/0 y 1.09 ( ) ( ).5542 Quartile 4/0 y 0.72 ( ) ( ).5127 Quartile 1/1 19 y 1.87 ( ) ( ).2204 Quartile 2/1 19 y 1.53 ( ) ( ).3209 Quartile 3/1 19 y 2.23 ( ) ( ).3579 Quartile 4/1 19 y 1.30 ( ) ( ).7334 Quartile 1/ 20 y 0.76 ( ) ( ).8435 Quartile 2/ 20 y 1.47 ( ) ( ).6912 Quartile 3/ 20 y 1.30 ( ) ( ).6244 Quartile 4/ 20 y 3.03 ( ) ( ).0012 NOTE. A 2-tailed P value of less than.05 was considered statistically significant (bolded). a Adjustment for age, serum ALT level, serum HBV DNA level, and cirrhosis at entry. b WHO BMI categories: normal weight is BMI less than 23 kg/m 2, overweight is BMI of 23 to less than 25 kg/m 2, obese includes BMI of 25 to less than 30 kg/m 2, and extremely obese includes BMI of 30 kg/m 2 or greater. c Participants are classified into quartiles of BMI: quartile 1 (lowest BMI: referent group) and quartile 4 (highest BMI category) ; P.0042). We also analyzed the joint association between BMI (classified into quartiles) and duration of alcohol use and found that the risk of HCC was highest in the patients in the highest BMI quartile (quartile 4) who drank more than 20 years (HR, 4.5; 95% CI, ) as shown in Supplementary Figure 3. The risk of HCC was higher in quartiles 2, 3, and 4 with a history of 20 or more years of alcohol use and synergistically increased with a higher BMI (P for trend.027).

6 896 LOOMBA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 10 Figure 3. Participants are classified into weight categories suggested by WHO for Asian populations. Normal weight is BMI less than 23 kg/m 2, overweight is BMI of 23 to less than 25 kg/m 2, obese includes BMI of 25 to less than 30 kg/m 2, and extremely obese includes BMI of 30 kg/m 2 or greater. This figure shows that risk of incident HCC increases as BMI dose increases only in alcohol users (P value for trend.046). The joint association between highest BMI quartile and 20 or more years of alcohol use remained statistically significant in both age-adjusted (HR, 3.03; 95% CI, , P.0025) and multivariable-adjusted analyses (HR, 3.29; 95% CI, ; P.0015) as shown in Table 3. Discussion Main Findings In this prospective population-based cohort of HBsAgpositive Asian men residing in Taiwan, we showed an interaction between BMI and alcohol use with the risk of incident HCC. We found that extreme obesity (BMI, 30 kg/m 2 ) and alcohol consumption synergistically increase the risk of incident HCC over 14 years of follow-up evaluation. This study showed that the interaction between obesity and alcohol with risk of incident HCC is multiplicative. Our findings show that the risk of HCC among alcohol users is highest among the extremely obese, and this risk decreases as BMI approaches the normal weight category, suggesting that prevention of obesity and minimizing alcohol use among patients with hepatitis B may reduce the burden of HCC worldwide. In Context With Published Literature Previous epidemiologic studies provide a significant association between male sex, Asian ethnicity, obesity, higher alcohol use, increased ALT, HBeAg status, HBV-DNA levels, and presence of cirrhosis as important risk factors for future development of HCC in patients with or without viral hepatitis. 10,11,27,28 These risk factors were also significant predictors of HCC in this cohort. Hepatitis B infection is the leading cause of HCC worldwide. Both obesity and alcohol use are independent and modifiable risk factors for fatty liver disease as well as future development of HCC. 29 Because of the global obesity and fatty liver epidemic, the joint effect of obesity and alcohol on future risk of HCC is of important public health significance. El-Serag 30 has shown that the incidence and mortality from HCC are increasing and will continue to increase in the next 2 decades. This increase in the burden of HCC in the United States parallels the increasing rates of obesity. 4,31 It is possible that increasing rates of obesity may further fuel the increase of increasing HCC rates. Mechanism It is possible that obesity and alcohol synergistically augment cytokine balance within the liver and increase the risk of HCC in predisposed individuals. Both obesity and alcohol lead to oxidative stress and progressive liver injury via multiple inter-related metabolic pathways such as cytochrome P450 2E1 induction, free radical generation, lipid peroxidation, nuclear factor- B activation, and increased transcription of proinflammatory mediators, including tumor necrosis factor- 32,33 Dietinduced obesity is known to accentuate the progression of alcoholic liver injury via free radical damage, increasing tumor necrosis factor- production, and worsening insulin resistance. Some of the earlier-mentioned pathways such as nuclear factor- B, tumor necrosis factor-, and interleukin-6 have been directly implicated in tumorigenesis and perhaps may be involved in the pathogenesis of HCC. 34 Our study provides epidemiologic evidence to pursue these hypotheses. Obesity and alcohol may increase the risk of both alcoholic liver disease and NAFLD. Emerging data suggest that NAFLD increases the risk of HCC. Marrero et al 13 have shown that NAFLD is present in 11% of HCC patients. Previous studies have suggested that HCC cases in the setting of cryptogenic cirrhosis may in fact be related to NAFLD because cryptogenic cirrhosis may represent burnt out NASH in a subset of patients. 15 A Danish cohort study including 7326 patients discharged from the hospital with a diagnosis of fatty liver showed that patients with fatty liver had a significantly increased standardized incidence ratio of A recent Japanese study estimated the risk of HCC in NASH patients over 5 years of follow-up evaluation to be 7.6%. 16 Therefore, the epidemiologic link between NAFLD and HCC is becoming stronger as newer data are emerging. Strengths and Limitations Strengths of our study included prospective follow-up evaluation over 14 years, large sample size, body mass index recorded by a trained investigator and not by self-report, availability of known risk factors of HCC at baseline for adjustment in multivariate analyses, and a well-characterized cohort. In addition, previous findings derived from this cohort have been generalizable to other populations, and have been reproduced in independent cohorts, and well accepted by independent investigators. However, we acknowledge the following limitations of our study, which include that alcohol use was based on self-report. Lifetime alcohol use and binge drinking could not be quantified accurately. This is likely to underestimate the quantity of alcohol use and potentially could lead to misclassification bias. However, underreporting and misclassification (heavier alcohol users classified as nonusers) is likely to favor a null finding (no effect of alcohol use on HCC risk) rather than a synergistic effect of the alcohol exposure and obesity. Therefore, it is possible that our study may underestimate the synergism between obesity and alcohol use. However, it can be safely concluded based on data from a previous case-control study by Marrero et al 36 and our prospective cohort study that obesity and alcohol use are synergistic. The prevalence of obesity is lower in this population and the relative increase in HCC risk in obese versus nonobese (especially in nonusers of alcohol) is not statistically significant among Taiwanese men with hepatitis B. However, alcohol appears to be particularly harmful in obese versus nonobese individuals, suggesting a double hit in

7 October 2010 OBESITY, ALCOHOL, AND HCC RISK 897 increasing the susceptibility to develop steatohepatitis that may multiply the risk of HCC in obese drinkers. Because women were not included in this analysis, further studies are needed to address whether the synergism between alcohol and obesity is sex-specific or independent. We were not able to examine the effect of obesity and alcohol in women because both the prevalence and quantity of alcohol use among Taiwanese HBsAgpositive women were extremely low. Therefore, women were excluded from these analyses. It remains to be determined whether the observed interaction between obesity and alcohol also is seen in patients with chronic hepatitis C because our study population did not include patients with hepatitis C virus infection. Future studies are needed in a large multi-ethnic cohort to accurately quantify the effects of obesity and alcohol on HCC risk in participants with or without viral hepatitis. Conclusions This study provides epidemiologic evidence of a multiplicative interaction between alcohol use and obesity in increasing HCC risk in HBsAg-positive men. These findings suggest that lifestyle intervention programs that encourage weight loss in obese or overweight in high risk individuals and endorse abstaining from alcohol use can be expected to lower the risk of future development of HCC. Given the expected increase in HCC incidence over the next 2 decades, public health interventions are needed to reduce the burden of HCC in endemic areas. Supplementary Material Note: to access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at and at doi: / j.cgh References 1. WHO. The global burden of disease: 2004 update. In: Geneva S, ed. Health statistics and informatics department WHO. Geneva: WHO Press, Available at: bod. Accessed August 23, El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139: Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 2009;136: Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to J Clin Oncol 2009;27: Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135: Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348: Larsson SC, Wolk A. Overweight, obesity and risk of hepatocellular carcinoma: a meta-analysis of cohort studies. Br J Cancer 2007;97: Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85: Jee SH, Ohrr H, Sull JW, et al. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004;96: Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007;146: Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145: Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36: El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009;44(Suppl 19): Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther 2009;30: Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347: Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295: WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363: Wang LY, You SL, Lu SN, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAgseronegative male residents in Taiwan. Cancer Causes Control 2003;14: Lin DY, Sheen IS, Chiu CT, et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993;21: Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11: , viii. 24. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980;112: Richardson DB, Kaufman JS. Estimation of the relative excess risk due to interaction and associated confidence bounds. Am J Epidemiol 2009;169: de Mutsert R, Jager KJ, Zoccali C, et al. The effect of joint exposures: examining the presence of interaction. Kidney Int 2009;75: Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98: El-Serag HB, Mason AC. Risk factors for the rising rates of primary hepatocellular carcinoma in the United States. Arch Intern Med 2000;160: Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155: El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27 S Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, JAMA 2006;295: Purohit V, Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 2006;43:

8 898 LOOMBA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No Siegmund SV, Brenner DA. Molecular pathogenesis of alcoholinduced hepatic fibrosis. Alcohol Clin Exp Res 2005;29:102S 109S. 34. Naugler WE, Karin M. The wolf in sheep s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14: Sorensen HT, Mellemkjaer L, Jepsen P, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003;36: Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42: Reprint requests Address requests for reprints to: Rohit Loomba, MD, MHSc, Division of Gastroenterology and Division of Epidemiology, University of California at San Diego, 9500 Gilman Drive, MC 0063, La Jolla, California roloomba@ucsd.edu; fax: (858) ; or Chien-Jen Chen, ScD, Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan. fax: (886) Conflicts of interest The authors disclose no conflicts. Funding This work is supported in part by the American Gastroenterological Association Foundation Sucampo Association of Specialty Professors Designated Research Award in Geriatric Gastroenterology and by a T. Franklin Williams Scholarship Award. Funding also provided by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of Specialty Professors, and the American Gastroenterological Association (R.L.). The REVEAL-HBV study was supported by a grant from the Department of Health, Academia Sinica, National Health Research Institutes in Taiwan, and Bristol-Myers Squibb Company, Wallingford, CT.

9 898.e1 LOOMBA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 10 Supplementary Figure 1. Joint effect of BMI categories and duration of alcohol use with risk of HCC. Participants are classified into weight categories suggested by WHO for Asian populations. Normal weight is BMI less than 23 kg/m 2, overweight is BMI of 23 to less than 25 kg/m 2, obese includes BMI of 25 to less than 30 kg/m 2, and extremely obese includes BMI of 30 kg/m 2 or greater. This figure shows that risk of incident HCC increases as BMI dose increases in individuals with 20 or more years of alcohol use (P value for trend.006). Within each weight category, the risk of HCC increased with greater duration of alcohol use as well. Supplementary Figure 2. Joint effect of BMI quartiles and alcohol use with risk of HCC in men. Participants are classified into quartiles of BMI: quartile 1 (lowest BMI: referent group) and quartile 4 (highest BMI category). This figure shows that risk of incident HCC increases as BMI dose increases only in alcohol users (P value for trend.08).

10 October 2010 OBESITY, ALCOHOL, AND HCC RISK 898.e2 Supplementary Figure 3. Joint effect of BMI quartiles and duration of alcohol use with risk of HCC in men. Participants are classified into quartiles of BMI: quartile 1 (lowest BMI: referent group) and quartile 4 (highest BMI category). This figure shows that risk of incident HCC increases as BMI dose increases in individuals with 20 or more years of alcohol use (P value for trend.027). Within each weight category, the risk of HCC increased with greater duration of alcohol use except in the lowest quartile in which the effect of modification was clinically not significant.

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma

Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma GASTROENTEROLOGY 2011;141:1240 1248 Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma CHUEN FEI CHEN,*, WEN CHUNG LEE,* HWAI I YANG,, HUNG CHUEN

More information

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High

More information

Chronic infection with hepatitis B virus (HBV) is still a

Chronic infection with hepatitis B virus (HBV) is still a CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Hepatitis B virus (HBV) infection is a global

Hepatitis B virus (HBV) infection is a global VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung

More information

During the past 2 decades, an increase in the ageadjusted

During the past 2 decades, an increase in the ageadjusted CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection

Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:921 931 Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection UCHENNA H. ILOEJE,* HWAI I YANG, CHIN LAN JEN, JUN SU,* LI YU WANG,

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Association between obesity, hypertriglyceridemia and low hepatitis B viral load

Association between obesity, hypertriglyceridemia and low hepatitis B viral load International Journal of Obesity (2013) 37, 410 415 & 2013 Macmillan Publishers Limited All rights reserved 0307-0565/13 www.nature.com/ijo ORIGINAL ARTICLE Association between obesity, hypertriglyceridemia

More information

Chronic hepatitis B virus (HBV) infection remains a major

Chronic hepatitis B virus (HBV) infection remains a major CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01. NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual

More information

Liver disease is a major cause of mortality and morbidity

Liver disease is a major cause of mortality and morbidity CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:524 530 Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 ZOBAIR M. YOUNOSSI,*, MARIA

More information

Chronic hepatitis B (CHB) infection is a large

Chronic hepatitis B (CHB) infection is a large AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information

UMHS-PUHSC JOINT INSTITUTE

UMHS-PUHSC JOINT INSTITUTE Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,

More information

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013 Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?

Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? Liver International ISSN 17-3223 REVIEW ARTICLE Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? Uchenna H. Iloeje 1, Hwai-I Yang 2,3 and Chien-Jen Chen,5 1 Global Health Economics

More information

Metabolic Syndrome and HCC. Jacob George

Metabolic Syndrome and HCC. Jacob George Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular

More information

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung

More information

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013 Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Available online at journal homepage:

Available online at   journal homepage: Kaohsiung Journal of Medical Sciences (2013) 29, 451e459 Available online at www.sciencedirect.com journal homepage: http://www.kjms-online.com ORIGINAL ARTICLE Diabetes mellitus, metabolic syndrome and

More information

STOP Hepatocellular Carcinoma

STOP Hepatocellular Carcinoma STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern

More information

T he incidence of hepatocellular carcinoma (HCC) has

T he incidence of hepatocellular carcinoma (HCC) has 533 LIVER Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study J A Davila, R O Morgan, Y Shaib, K A McGlynn, H B El-Serag... See end of article

More information

The New England Journal of Medicine. HEPATITIS B e ANTIGEN AND THE RISK OF HEPATOCELLULAR CARCINOMA

The New England Journal of Medicine. HEPATITIS B e ANTIGEN AND THE RISK OF HEPATOCELLULAR CARCINOMA HEPATITIS B e ANTIGEN AND THE RISK OF HEPATOCELLULAR CARCINOMA HWAI-I YANG, M.SC., SHENG-NAN LU, M.D., PH.D., YUN-FAN LIAW, M.D., SAN-LIN YOU, PH.D., CHIEN-AN SUN, SC.D., LI-YU WANG, PH.D., CHUHSING K.

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011 HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary

More information

HCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study

HCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV

More information

Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan

Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan Shu-Fen Liao 1, Hwai-I Yang 2, Mei-Hsuan Lee 3, Chien-Jen

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans

Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans Clinical Gastroenterology and Hepatology 2016;14:301 308 Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans Fasiha Kanwal,*,, Jennifer R. Kramer,*, Zhigang Duan,*,

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease (NAFLD) HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,

More information

Hepatitis B virus (HBV) is a major public health

Hepatitis B virus (HBV) is a major public health Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus Infected Compensated Cirrhosis Patients With Low Viral Load Dong Hyun Sinn, 1 Junggyu Lee, 1 Juna Goo, 2 Kyunga Kim, 2 Geum-Youn Gwak, 1 Yong-Han

More information

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay

More information

Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States

Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States Maria Stepanova, 1,2 Stephen Clement, 3 Robert Wong, 4 Sammy Saab,

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Alam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1

Alam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1 Bangladesh Med Res Counc Bull 2014; 40: 92-56 Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase

More information

Cigarette Smoking And Hepatocellular Carcinoma Risk In Xiamen, China

Cigarette Smoking And Hepatocellular Carcinoma Risk In Xiamen, China Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2012 Cigarette Smoking And Hepatocellular Carcinoma Risk In Xiamen, China

More information

ORIGINAL INVESTIGATION. Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection

ORIGINAL INVESTIGATION. Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection ORIGINAL INVESTIGATION Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection Implications for Prevention of Hepatitis C Virus Progression Chong-Shan Wang, MD, MPH; Shan-Tair Wang,

More information

Perceptions of cancer risk and self-care practices: comparison of groups at different risk for cancers

Perceptions of cancer risk and self-care practices: comparison of groups at different risk for cancers Title Perceptions of risk and self-care practices: comparison of groups at different risk for s Author(s) Fielding, R; Lam, WWT; Liao, Q; Lai, CL; Tsang, WHJ; Ip, DKM; Yuen, RMF Citation Hong Kong Medical

More information

Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea

Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea Sun Ha Jee, Heechoul Ohrr, Jae Woong Sull, Jonathan M. Samet Background: Liver cancer is one of the most

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma

Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma Tumor Factors Associated with Clinical Outcomes in Patients with Hepatitis B Virus Infection and Hepatocellular Carcinoma Myron John Tong, PhD, MD, Surachate Siripongsakun, MD, Gaelen Stanford-Moore, BA,

More information

Why Do We Treat Obesity? Epidemiology

Why Do We Treat Obesity? Epidemiology Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population

More information

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Yao-Shih Hsu, 1 Rong-Nan Chien, 1 Chau-Ting Yeh, 1 I-Shyan Sheen, 1 Hung-Yi Chiou, 2 Chia-Ming Chu, 1 and Yun-Fan

More information

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding

More information

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based

More information

American Journal of Oral Medicine and Radiology

American Journal of Oral Medicine and Radiology American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION

More information

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis

More information

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1

More information

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과

More information

Hepatitis C Virus Infection in Diabetes Mellitus Patients

Hepatitis C Virus Infection in Diabetes Mellitus Patients 599 Hepatitis C Virus Infection in Diabetes Mellitus Patients Han Ni*, Soe Moe, Aung Htet 1 Assistant Professor, Department of Medicine, Melaka Manipal Medical College, Malaysia 2 Associate Professor,

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

YOUNG ADULT MEN AND MIDDLEaged

YOUNG ADULT MEN AND MIDDLEaged BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,

More information

M easurements of serum aspartate aminotransferase

M easurements of serum aspartate aminotransferase 774 ORIGINAL ARTICLE Synergistic effect of hepatitis virus infection and occupational exposures to vinyl chloride monomer and ethylene dichloride on serum aminotransferase activity H-I Hsieh, J-D Wang,

More information

Hepatocellular carcinoma (HCC) is a leading. Development of Risk Scoring System for Stratifying Population for Hepatocellular Carcinoma Screening

Hepatocellular carcinoma (HCC) is a leading. Development of Risk Scoring System for Stratifying Population for Hepatocellular Carcinoma Screening Development of Risk Scoring System for Stratifying Population for Hepatocellular Carcinoma Screening Yi-Chun Hung, 1 Chih-Lin Lin, 2 Chun-Jen Liu, 3 Hung Hung, 1 Shi-Ming Lin, 4 Shou-Dong Lee, 5,6 Pei-Jer

More information

Hepatitis B virus (HBV) infection is an important. Brief Communication

Hepatitis B virus (HBV) infection is an important. Brief Communication Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,

More information

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute

More information

PREVALENCE OF NAFLD & NASH

PREVALENCE OF NAFLD & NASH - - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:285 290 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Serum Levels of Alanine Aminotransferase Decrease With Age in Longitudinal Analysis MAMIE H.

More information

Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men

Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men Carcinogenesis vol.29 no.1 pp.106 112, 2008 doi:10.1093/carcin/bgm252 Advance Access publication November 13, 2007 Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD CLINICAL OFFICES Digestive Health Liver Clinic 900 Blake Wilbur Dr MC 5355 Palo Alto, CA 94304 Tel (650) 498-7999 Fax (650) 724-9454 Liver Transplant Clinic 300 Pasteur Dr A160 Bio MC 5309 Stanford, CA

More information

February 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:

February 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi: February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance

More information

Chronic hepatitis B (CHB) is the leading cause of

Chronic hepatitis B (CHB) is the leading cause of GASTROENTEROLOGY 2013;144:933 944 CLINICAL LIVER Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment GRACE LAI HUNG WONG, 1,2 HENRY LIK YUEN CHAN, 1,2 HOI YUN CHAN,

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis

More information

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,

More information